drugset / Trial / NCT01291914

Study of FX005 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

NCT01291914 ↗

Phase 1/2 Completed 140 enrolled Pacira Pharmaceuticals, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of FX005 for the treatment of pain in patients with osteoarthritis of the knee.

Timeline

Start
2010-12
Primary completion
2012-01
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject FX005 Unknown 1 mg Other
Subject FX005 Unknown 10 mg Other
Subject FX005 Unknown 45 mg Other

Indications